BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) en Acepodia (6976:TT) hebben vandaag een baanbrekend strategisch partnerschap aangekondigd om gezamenlijk een programma voor dual-payload bispecifieke antilichaam-geneesmiddelconjugaten (BsAD2C) te beoordelen. Deze samenwerking combineert het RenLite®-platform van Biocytogen met de Antibody-Dual-Drugs Conjugation (AD2C)-technologie van Acepodia om enkele van de moeilijkste uitdagingen in de oncologie aan te pakken: tu

ST. LOUIS & HERCULES, Calif.–(BUSINESS WIRE)–Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories

COLUMBIA, Md.–(BUSINESS WIRE)–Propelled by historic expansion of its reach across diverse systems and state lines, CRISP Shared Services (CSS) today announced significant progress throughout 2024 toward its mission of providing localized and impactful health infrastructure and data exchange technology across the United States. CSS continued its impactful work with CRISP, Maryland’s state-designated health information exchange (HIE) and Health Data Utility (HDU); CRISP DC, serving the District

PECHINO, ALAMEDA, California e TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) e Acepodia (6976:TT) oggi hanno annunciato l’inizio di una rivoluzionaria partnership strategica finalizzata a valutare congiuntamente un programma di sviluppo di coniugati farmaco-anticorpo bispecifico con doppio payload (BsAD2C). Questa collaborazione combina la piattaforma Biocytogen RenLite® con la tecnologia dei coniugati farmaco-anticorpo doppio (AD2C) Acepodia per risolvere alcuni dei problemi più complessi

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes, LLC and YAP Therapeutics, Inc. have entered into a collaboration agreement to develop and produce radiopharmaceuticals aimed at treating cancer and other chronic diseases. NorthStar is involved in the development, production, and commercialization of radiopharmaceuticals for therapeutic applications and medical imaging. YAP Therapeutics, a Fjord Ventures company, utilizes its advanced biologic and regenerativ

BOSTON–(BUSINESS WIRE)–MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Brian Shuster will join the Company as Entrepreneur Partner. Brian currently serves as Chief Business Officer of MPM BioImpact portfolio company Orna Therapeutics. “We are delighted to welcome Brian, a tenured biotechnology executive and expert in strategic business development, to MPM BioImpact. With

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 20

BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a

FARMINGTON, Conn.–(BUSINESS WIRE)–Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to Onkos Surgical (“Onkos”), of which $30 million h

TORONTO–(BUSINESS WIRE)–Breast Cancer Canada is committed to its mission to advance breast cancer research, advocacy, and equitable access in 2025.